HSP90AB1 and chronic myelogenous leukemia, BCR-ABL1 positive: The concentration of 17AAG was controlled within 10uM and treated within 6H, which could maintain the CML cells in a relatively stable state and inhibit the function of HSP90AB1 (Fig. 3a).